Bibliography
- Hirschfeld RM, Calabrese JR, Weissman MM, Screening for bipolar disorder in the community. J Clin Psychiatry 2003;64:53-9
- Ghaemi SN, Boiman EE, Goodwin FK. Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. J Clin Psychiatry 2000;61:804-8
- Eli Lilly and Co. Symbyax (olanzapine and fluoxetine). Revised August 2011. Available from: http://pi.lilly.com/us/symbyax-pi.pdf [Last accessed 12 September 2011]
- AstraZeneca. Seroquel (quetiapine). Revised July 2011. Available from: http://www1.astrazeneca-us.com/pi/Seroquel.pdf [Last accessed 12 September 2011]
- AstraZeneca. Seroquel XR (quetiapine extended release). Revised July 2011. Available from: http://www1.astrazeneca-us.com/pi/seroquelxr.pdf [Last accessed 12 September 2011]
- Eli Lilly and Co. Zyprexa (olanzapine). Revised June 2011. Available from: http://pi.lilly.com/us/zyprexa-pi.pdf [Last accessed 12 September 2011]
- Citrome L. Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad Med 2010;122:39-48
- Tohen M, Vieta E, Calabrese J, Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60:1079-88
- Brown EB, McElroy SL, Keck PE Jr, A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006;67:1025-33
- Brown E, Dunner DL, McElroy SL, Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression. Int J Neuropsychopharmacol 2009;12:773-82
- Eli Lilly and Co. Summary ID#3077. Clinical Study Summary: Study F1D-MC-HGGY (acute). Available from: http://www.clinicalstudyresults.org/documents/company-study_169_0.pdf [Last accessed 12 September 2011]
- Eli Lilly and Co. Summary ID# 7980. Clinical Study Summary: Study H6P-US-HDAQ. Available from: http://www.clinicalstudyresults.org/documents/company-study_1540_0.pdf [Last accessed 12 September 2011]
- Citrome L, Holt RI, Walker DJ, Hoffmann VP. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. Clin Drug Investig 2011;31:455-82
- Kantrowitz JT, Citrome L. Olanzapine: review of safety 2008. Expert Opin Drug Saf 2008;7:761-9
- Citrome L. Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications. Curr Drug Saf 2009;4:229-37
- Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 2009;194:4-9
- Ketter TA, Citrome L, Wang PW, Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions? Acta Psychiatr Scand 2011;123:175-89
- GlaxoSmithKline. Lamictal (lamotrigine). Revised July 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020241s047,020764s040,022251s010lbl.pdf [Last accessed 12 September 2011]
- Citrome L. Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr Scand 2008;117:412-19
- Thase ME, Jonas A, Khan A, Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008;28:13-20
- Sachs G, Lombardo I, Yang R, Kremer C. Learnings from the ziprasidone bipolar I depression clinical trials program. Poster presentation II-13. 49th Annual NCDEU Meeting; 2009 June 29-July 2; Hollywood, Florida
- Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract 2011;65:189-210